These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 9179233

  • 1. Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re-186-HEDP.
    De Klerk JM, Zonnenberg BA, Blijham GH, Van Het Schip AD, Hoekstra A, Han SH, Quirijnen JM, Van Dijk A, Van Rijk PP.
    Anticancer Res; 1997; 17(3B):1773-7. PubMed ID: 9179233
    [Abstract] [Full Text] [Related]

  • 2. Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer.
    de Klerk JM, van het Schip AD, Zonnenberg BA, van Dijk A, Quirijnen JM, Blijham GH, van Rijk PP.
    J Nucl Med; 1996 Feb; 37(2):244-9. PubMed ID: 8667053
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases.
    de Klerk JM, van Dijk A, van het Schip AD, Zonnenberg BA, van Rijk PP.
    J Nucl Med; 1992 May; 33(5):646-51. PubMed ID: 1373767
    [Abstract] [Full Text] [Related]

  • 4. 186Re-etidronate. Efficacy of palliative radionuclide therapy for painful bone metastases.
    Han SH, De Klerk JM, Zonnenberg BA, Tan S, Van Rijk PP.
    Q J Nucl Med; 2001 Mar; 45(1):84-90. PubMed ID: 11456380
    [Abstract] [Full Text] [Related]

  • 5. Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts.
    de Klerk JM, van Dieren EB, van het Schip AD, Hoekstra A, Zonnenberg BA, van Dijk A, Rutgers DH, Blijham GH, van Rijk PP.
    J Nucl Med; 1996 Jan; 37(1):38-41. PubMed ID: 8543998
    [Abstract] [Full Text] [Related]

  • 6. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate.
    Palmedo H, Manka-Waluch A, Albers P, Schmidt-Wolf IG, Reinhardt M, Ezziddin S, Joe A, Roedel R, Fimmers R, Knapp FF, Guhlke S, Biersack HJ.
    J Clin Oncol; 2003 Aug 01; 21(15):2869-75. PubMed ID: 12885803
    [Abstract] [Full Text] [Related]

  • 7. [186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast.
    Minutoli F, Herberg A, Spadaro P, Restifo Pecorella G, Baldari S, Aricò D, Altavilla G, Baldari S.
    Q J Nucl Med Mol Imaging; 2006 Dec 01; 50(4):355-62. PubMed ID: 17043634
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Application of rhenium-188 HEDP in bone metastases therapy.
    Scheffler J, Derejko M, Bandurski T, Romanowicz G.
    Nucl Med Rev Cent East Eur; 2003 Dec 01; 6(1):55-7. PubMed ID: 14600935
    [Abstract] [Full Text] [Related]

  • 11. Transient cranial neuropathy in prostatic cancer with bone metastases after rhenium-186-HEDP treatment.
    de Klerk JM, Zonnenberg BA, Krouwer HG, Blijham GH, van Dijk A, van het Schip AD, van Die J, van Rijk PP.
    J Nucl Med; 1996 Mar 01; 37(3):465-7. PubMed ID: 8772646
    [Abstract] [Full Text] [Related]

  • 12. 186Re-HEDP for metastatic bone pain in breast cancer patients.
    Lam MG, de Klerk JM, van Rijk PP.
    Eur J Nucl Med Mol Imaging; 2004 Jun 01; 31 Suppl 1():S162-70. PubMed ID: 15118846
    [Abstract] [Full Text] [Related]

  • 13. A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer.
    Buffa FM, Flux GD, Guy MJ, O'Sullivan JM, McCready VR, Chittenden SJ, Dearnaley DP.
    Eur J Nucl Med Mol Imaging; 2003 Aug 01; 30(8):1114-24. PubMed ID: 12761596
    [Abstract] [Full Text] [Related]

  • 14. [Pain therapy with rhenium-186 HEDP in multiple bone metastases].
    Palmedo H, Bender H, Schomburg A, Grünwald F, Schöneich G, Zamorra P, Reichmann K, Dierke-Dzierzon C, Mallmann P, Biersack HJ.
    Nuklearmedizin; 1996 Apr 01; 35(2):63-7. PubMed ID: 8721578
    [Abstract] [Full Text] [Related]

  • 15. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.
    Liepe K, Hliscs R, Kropp J, Runge R, Knapp FF, Franke WG.
    J Nucl Med; 2003 Jun 01; 44(6):953-60. PubMed ID: 12791825
    [Abstract] [Full Text] [Related]

  • 16. Palliative analgesic effect of Re-186 HEDP in various cancer patients with bone metastases.
    Küçük NO, Ibiş E, Aras G, Baltaci S, Ozalp G, Bedük Y, Canakci N, Soylu A.
    Ann Nucl Med; 2000 Aug 01; 14(4):239-45. PubMed ID: 11023023
    [Abstract] [Full Text] [Related]

  • 17. 186Re-etidronate in breast cancer patients with metastatic bone pain.
    Han SH, Zonneberg BA, de Klerk JM, Quirijnen JM, van het Schip AD, van Dijk A, Blijham GH, van Rijk PP.
    J Nucl Med; 1999 Apr 01; 40(4):639-42. PubMed ID: 10210223
    [Abstract] [Full Text] [Related]

  • 18. [Palliation of bone pain in metastatic prostate carcinoma. Value of radionuclide therapy with rhenium 186 HEDP].
    Klutmann S, Bohuslavizki KH.
    MMW Fortschr Med; 1999 Nov 04; 141(44):38-9. PubMed ID: 10912142
    [Abstract] [Full Text] [Related]

  • 19. Dosage and response in radiopharmaceutical therapy of painful osseous metastases.
    Silberstein EB.
    J Nucl Med; 1996 Feb 04; 37(2):249-52. PubMed ID: 8667054
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.